louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03247426: Sleep Quality, Job Satisfaction, Quality of Life, Occupational Burnout Levels in Individuals
Official title: Comparison of Sleep Quality, Job Satisfaction, Quality of Life, Occupational Burnout Levels Among Individuals Who do or do Not do Exercise
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Physical Activity
Lead sponsor: Hacettepe University
Sponsor class: OTHER
First posted: 2017-08-11
Enrollment: 109
Sex: ALL
Minimum age (years): 25
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Healthy individuals who aged between 25-65 years, are in the profession group working for at least 8 hours, do the same job for at least 5 years, and having no doctor-diagnosed skeletal system disease will be included.

Brief summary: The aim of this study is to compare sleep quality, job satisfaction, quality of life, occupational burnout levels among individuals who do or do not do exercise.

Detailed description: Physical activity is very important in terms of healthy growth and development, protection from unwanted bad habits, socialization, protection from chronic diseases, and providing an active aging period. At the same time it increases the quality of life throughout life.Especially in individuals who work in sitting position, the risk of physical activity decrease due to intensive working hours, time constraint, social insufficiency is even more risk.Therefore, it is aimed to compare sleep quality, job satisfaction, quality of life, occupational burnout levels among individuals who do or do not do exercise.

Eligibility criteria: Inclusion Criteria:

Healthy individuals;

* Between the ages of 25-65 years,
* Those who are in the profession group working for at least 8 hours,
* who do the same job for at least 5 years,
* Individuals with no doctor-diagnosed skeletal system disease will be included.

Exclusion Criteria:

Individuals;

* Below the age of 25 years and above the age of 65 years,
* Individuals with doctor-diagnosed skeletal system disease will be excluded.

Primary outcomes:
measure: Sleep quality of the individuals
timeFrame: 15 days
Secondary outcomes:
measure: job satisfaction
timeFrame: 15 days
measure: quality of life
timeFrame: 15 days
measure: occupational burnout level
timeFrame: 15 days
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Hacetttepe University
Study officials:
affiliation: Hacettepe University
name: SELEN SEREL ARSLAN
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00187226: A Study for Image-Guided Radiation Therapy in Pediatric Brain Tumors and Side Effects
Official title: A Phase II Study of Image-Guided Radiation Therapy for Pediatric CNS Tumors and Quantification of Radiation-Related CNS Effects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Central Nervous System Tumors
Brain Tumors
Keywords: Brain neoplasm
Brain cancer
Neoplasm intracranial
Lead sponsor: St. Jude Children's Research Hospital
Sponsor class: OTHER
First posted: 2005-09-16
Enrollment: 361
Sex: ALL
Minimum age (years): 8
Maximum age (years): 25
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of the study was to determine if treating a limited volume of normal tissue surrounding the tumor or tumor bed using conformal radiation therapy would achieve similar rates of disease control compared to standard radiation therapy. The study was also conducted to examine the effect of irradiation on neurological, endocrine and cognitive function.

Detailed description: Radiation therapy is commonly used to treat a variety of brain tumors in children including ependymoma, craniopharyngioma and low- and high-grade glioma. The ability of the therapy to control brain tumors in children is known to depend on the tumor type, extent of resection and other clinical factors. Children who received radiation therapy on this study were evaluated for treatment failure at 12 months. In addition to the primary objective, the study was designed to explore the association between radiation dose and volume and a variety of neurological, endocrine and cognitive deficits up to 5 years after treatment.

Eligibility criteria: Inclusion Criteria:

* Age at time of irradiation is greater than or equal to 8 months and less than or equal to 25 years
* Histologically diagnosed craniopharyngioma, ependymoma, low-grade astrocytoma or high-grade glioma and radiographically diagnosed selected patients with craniopharyngioma and low-grade glioma.
* Adequate performance status, participant has an ECOG (Performance Status Score) of 0-2(0=Normal Activity; 1=Symptoms but Ambulatory; 2=Bedridden \<50% of time)
* Histologic type that requires only focal irradiation.
* No prior fractionated external beam irradiation
* Informed consent signed by patient, parent, or guardian.

Primary outcomes:
measure: Local Tumor Control
timeFrame: 12 months after the enrollment of the last therapeutic patient
Secondary outcomes:
Other outcomes:
Locations:
city: Memphis
country: United States
facility: St. Jude Children's Research Hospital
state: Tennessee
Study officials:
affiliation: St. Jude Children's Research Hospital
name: Thomas E. Merchant, D.O., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Netson KL, Conklin HM, Wu S, Xiong X, Merchant TE. Longitudinal investigation of adaptive functioning following conformal irradiation for pediatric craniopharyngioma and low-grade glioma. Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1301-6. doi: 10.1016/j.ijrobp.2012.10.031. Epub 2012 Dec 11.
Clinical trial NCT02113826: Pazopanib for Metastatic Alveolar Soft Part Sarcoma
Official title: A Phase II Trial of Pazopanib in Patients With Metastatic Alveolar Soft Part Sarcoma
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Metastatic Alveolar Soft Part Sarcoma
Keywords: Pazopanib
Alveolar soft part sarcoma
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
Collaborators: name: Seoul National University Bundang Hospital
name: Asan Medical Center
name: Samsung Medical Center
name: Severance Hospital
First posted: 2014-04-15
Enrollment: 6
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Alveolar soft part sarcoma (ASPS), a rare subset of STS (\<1%) harbors t(X;17)(p11;q25) translocation and produces resultant ASPL-TFE3 fusion protein. Due to its nature of high expression of angiogenic factors, sunitinib and cediranib produced overall response rates of 55% and 43%, respectively. However, the efficacy of pazopanib is unknown in metastatic ASPS.

Detailed description: Pazopanib, a multi-targeted anti-angiogenesis inhibitor significantly prolonged progression-free survival (PFS) in patients with metastatic soft-tissue sarcoma (STS) after failure to anthracycline-based regimen (pazopanib vs placebo, 4.6 vs 1.6 months, HR=0.31, 95% CI 0.24-0.40; P \< .0001). Regarding sunitinib (continuous daily dose of 37.5mg), after a median duration of 10 months, median OS and PFS were 19 months and 17 months, respectively in a small retrospective study (ASPS, N=9). With regard to cediranib, 6-month PFS was over 60%. In addition, randomized phase II trial of sunitinib vs cediranib with cross-over at disease progression was recently initiated (NCT01391962). However, the efficacy of pazopanib is unknown in metastatic ASPS.

Eligibility criteria: Key Inclusion Criteria:

* Histologically confirmed diagnosis of alveolar soft part sarcoma harboring TFE3 fusion at stage IV or at relapse
* Age ≥ 18 years
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
* Measurable lesion defined by RECIST v1.1
* Chemo-naïve or prior chemotherapies
* Adequate organ function

Exclusion Criteria:

* Prior malignancies
* Active CNS disease
* High-risk for gastrointestinal bleeding
* Significant cardiovascular disease
* Uncontrolled hypertension
* Bleeding diathesis

Primary outcomes:
measure: Overall response rate (ORR)
timeFrame: One year
Secondary outcomes:
measure: Number of Participants with Adverse Events
timeFrame: One year
measure: Progression-free survival
timeFrame: 6 month
measure: Overall survival
timeFrame: Two years
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
References:
citation: Kim M, Kim TM, Keam B, Kim YJ, Paeng JC, Moon KC, Kim DW, Heo DS. A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma. Oncologist. 2019 Jan;24(1):20-e29. doi: 10.1634/theoncologist.2018-0464. Epub 2018 Sep 25.
Clinical trial NCT04482426: Correlates of Electrophysiological Activities in Different Pelvic Floor Muscle Groups and Female Pelvic Floor Function
Official title: Correlates of Electrophysiological Activities in Different Pelvic Floor Muscle Groups and Female Pelvic Floor Function
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pelvic Floor
Lead sponsor: Cathay General Hospital
Sponsor class: OTHER
First posted: 2020-07-22
Enrollment: 112
Sex: FEMALE
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women with pelvic floor dysfunction

Brief summary: The study aimed to explore and quantify functional and electrical activities in different pelvic floor muscle groups, to differentiate the electrophysiological role in different pelvic floor muscle groups relating to pelvic floor dysfunction or disorders, and further to develop treatment strategies for different pelvic floor muscle groups in different female pelvic disorders.

Detailed description: Female pelvic floor disorders including sexual dysfunction, urinary incontinence, fecal incontinence, and pelvic organ prolapse are relating to the function of pelvic floor structures. Essential components responsible for pelvic floor function include bony, muscular, and fascial structures of the pelvis. Among above components, pelvic floor muscles, either the superficial or deep group, are considered crucial in maintaining the morphology and functional integrity of the pelvic floor.

Inspection and digital examination incorporating Oxford grading system during pelvic examinations are the most convenient and commonly methods applied to evaluate the function of pelvic floor muscles. Nevertheless, both methods cannot provide quantitative information of pelvic floor muscle contraction. With the introduction of pelvic floor manometry and electrophysiological testing, quantification of pelvic floor muscle contractions can be expected.

The study aimed to explore and quantify functional and electrical activities in different pelvic floor muscle groups, to differentiate the electrophysiological role in different pelvic floor muscle groups relating to pelvic floor dysfunction or disorders, and further to develop treatment strategies for different pelvic floor muscle groups in different female pelvic disorders.

Eligibility criteria: Inclusion Criteria:

* Women with pelvic floor dysfuntion

Exclusion Criteria:

* Pregnant women
* Women with histories of diabetes, cerebrovascular diseases, neurological diseases, degenerative muscular diseases, or autoimmune connective tissue diseases。

Primary outcomes:
measure: Contraction of pelvic floor muscle
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06076226: A Retrospective Study on the Relationship Between Donor Leukocyte Telomere Length and Prognosis of Acute Leukemia Patients Treated With Allogeneic Hematopoietic Stem Cell Transplantation
Official title: The First Affiliated Hospital, Zhejiang University School of Medicine
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Acute Leukemia
Lead sponsor: Zhejiang University
Sponsor class: OTHER
First posted: 2023-10-10
Enrollment: 2500
Sex: ALL
Minimum age (years): 5
Maximum age (years): 90
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This study aims to investigate the influence of donor blood telomere length on recipients' clinical outcomes post-allogeneic hematopoietic stem cell transplant.

Brief summary: This post hoc analysis included patients with acute leukemia who underwent allo-HSCT at the First Affiliated Hospital of Zhejiang University School of Medicine and Ruijin Hospital Shanghai Jiaotong University School of Medicine. Patients and their donors were assessed for eligibility to join this study. The inclusion criteria were: (1) age ≥ 5 years; (2) diagnosis of acute leukemia including acute myeloid leukemia, acute lymphocytic leukemia, and mixed phenotype acute leukemia; (3) patients attained complete remission (CR) and achieved full engraftment with 100% donor chimerism following allo-HSCT; (4) telomere testing was conducted on peripheral leukocytes of donors before granulocyte colony-stimulating factor (G-CSF) mobilization, and the results were obtained. Written informed consent was obtained from all included patients and their donors, and the study was conducted in compliance with the Declaration of Helsinki. Ethical approval was approved by the ethics review committee of the First Affiliated Hospital of Zhejiang University School of Medicine.


Eligibility criteria: Inclusion Criteria:

* Age ≥ 5 years
* First allo-HSCT from matched related, unrelated, or haploidentical donors
* Achievement of complete remission after allo-HSCT
* Donor blood sample collection before granulocyte colony-stimulating factor mobilization

Exclusion Criteria

* Non-acute leukemia diagnoses, including acute myeloid leukemia, acute lymphocytic leukemia, and mixed phenotype acute leukemia
* Failure to achieve engraftment with full donor chimerism after allo-HSCT
* Inability to extract DNA for telomere length analysis.

Primary outcomes:
measure: Overall survival
timeFrame: From date of transplantuntil the date of death from any cause, assessed up to 60 months.
Secondary outcomes:
measure: Relapse-free survival
timeFrame: From date of transplant until the date of relapse or death from any cause, assessed up to 60 months.
measure: Cumulative incidence of relapse
timeFrame: From date of transplant until the date of relapse, assessed up to 60 months.
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: Clinical research ethics committee of the first affiliated hospital, college of medicine, zhejiang University
state: Zhejiang
Study officials:
References:
Clinical trial NCT01189526: Comparison of Intravitreal Ranibizumab and Macular Laser Photocoagulation for ME Following Branch Retinal Vein Occlusion (BRVO)
Official title: A Randomized Trial Comparing Intravitreal Ranibizumab and Macular Laser Photocoagulation for the Treatment of Macular Edema Following Branch Retinal Vein Occlusion
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Branch Retinal Vein Occlusion
Keywords: Branch retinal vein occlusion
macular edema
intravitreal injection
ranibizumab
Lead sponsor: Seoul Retina Investigator Group
Sponsor class: NETWORK
Collaborators: name: Samsung Medical Center
name: Kyungpook National University Hospital
First posted: 2010-08-26
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is designed to evaluate the efficacy of intravitreal Ranibizumab in comparison with macular laser photocoagulation as treatments for macular edema secondary to branch retinal vein occlusion.

Characteristics of this study is as below

1. Multicenter, randomized clinical trial. (intravitreal Ranibizumab 0.5mg injection vs. macular laser photocoagulation)
2. After 48 weeks follow up, functional change(visual acuity)and anatomical change (central retinal thickness) would be evaluated


Eligibility criteria: Inclusion Criteria:

* Symptom duration \< 6 Months, \> 4 weeks
* Visual acuity - less than 20/40 (73 letters) more than 20/400 (19 letters) in ETDRS chart
* OCT - center involved retinal thickening : \> 250 micrometers
* clear media
* well controlled hypertension (\<140/90mmHg) and diabetes (6.5\<HbA1c\<9.5)
* willing to return for all scheduled visits

Exclusion Criteria:

* uveitis,NVG, exudative AMD, diabetic retinopathy, Irvine-Gass syndrome, OIS
* any malignancy
* previous treatment history - laser photocoagulation, intravitreal injection with any drug, vitrectomy
* vitreomacular traction or epiretinal membrane
* intraocular surgery in the study eye within 6 months
* uncontrolled glaucoma ( \> 30mmHg with anti-glaucoma medications)
* optic neuropathy, amblyopia
* A condition that in the opinion of the investigator would preclude a patient's participation in the study

Primary outcomes:
measure: Best Corrected Visual Acuity (ETDRS letters)
timeFrame: 48 weeks
Secondary outcomes:
measure: Retinal Thickening
timeFrame: 48 weeks
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
Study officials:
affiliation: Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine
name: Se Woong Kang, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Department of Ophthalmology, Kyungpook National University
name: Jae Pil Shin, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05640726: The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy
Official title: The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
Conditions: Rectal Cancer
Lead sponsor: Fujian Cancer Hospital
Sponsor class: OTHER_GOV
First posted: 2022-12-07
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To explore the efficacy and safety of radiotherapy followed by PD-1+ standard chemotherapy in the first-line treatment of initial unresectable rectal cancer liver metastases


Eligibility criteria: Inclusion Criteria:

* Histologically confirmed adenocarcinoma of the rectum；
* The clinical stage evaluated by MRI was T3-4 and/or N+ and M1a(only liver metastasis)；
* ECOG PS 0-2；
* CHild Pugh A；
* Estimated survival ≥3 months;
* Women of childbearing age should comply with contraceptive measures if pregnancy test is negative;
* Adequate organ and bone marrow functions, ecg, blood, biochemical and other basic tests are not contraindications of chemotherapy;
* Adherence to scheduled visits, treatment plans, laboratory tests, and other study procedures Willingness and ability.

Exclusion Criteria:

* Pregnant or lactating women;
* No previous antitumor therapy；
* No previous liver local therapy；
* No contraception during the reproductive period;
* patients known to have a history of allergy to any study drug, similar drug or excipient;
* Patients with risk of massive gastrointestinal bleeding or gastrointestinal obstruction;
* Patients with a history of thromboembolism, except those caused by PICC;
* Patients with active infection;
* Other conditions that the investigator determines are not suitable for inclusion in the study.

Primary outcomes:
measure: progression free survival
timeFrame: up to 36 months
Secondary outcomes:
measure: objective response rate
timeFrame: every 3 months (up to 36 months）
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03118726: Evaluation of Immediate Postpartum LARC Implementation Programs
Official title: Evaluation of Immediate Postpartum LARC Implementation Programs
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Post Partum Contraception
Keywords: LARC
New Mexico
Contraception
Lead sponsor: University of New Mexico
Sponsor class: OTHER
First posted: 2017-04-18
Enrollment: 21
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Hospitals working with the New Mexico Perinatal Collaborative (NMPC) on implementing immediate postpartum long-acting reversible contraception programs. All hospitals in New Mexico interested in implementing immediate postpartum LARC programs will be eligible to participate in the NPMC program evaluation. The study will evaluate the components of this implementation program at several New Mexico hospitals using a stepped wedge design, with components being introduced to each hospital one at a time.

Brief summary: This study will engage hospitals working with the New Mexico Perinatal Collaborative (NMPC) on implementing immediate postpartum long-acting reversible contraception programs. All hospitals in New Mexico interested in implementing immediate postpartum LARC programs will be eligible to participate in the NPMC program evaluation. The study will evaluate the components of this implementation program at several New Mexico hospitals using a stepped wedge design,with components being introduced to each hospital one at a time


Eligibility criteria: Inclusion Criteria:

* Hospital staff: Important individuals at New Mexico hospitals planning to implement immediate postpartum LARC programs, with an emphasis on diversity of administrative perspectives.
* If more than 4 potential participants are identified at one institution, additional participants may be included if their participation in the study is likely to contribute additional information (e.g. job title or background is different from other study participants)

Exclusion Criteria:

- Inability to speak and read English proficiently

Primary outcomes:
measure: Baseline immediate postpartum LARC Implementation
timeFrame: April 2017-December 2018
Secondary outcomes:
Other outcomes:
Locations:
city: Albuquerque
country: United States
facility: University of New Mexico
state: New Mexico
Study officials:
affiliation: University of New Mexico
name: Lisa Hofler, MD, MBA, MPH
role: PRINCIPAL_INVESTIGATOR
References: